We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
South Africa’s CPGR Turns to Cell-Culture Based Screening to Advance Drug Discovery and Development
News

South Africa’s CPGR Turns to Cell-Culture Based Screening to Advance Drug Discovery and Development

South Africa’s CPGR Turns to Cell-Culture Based Screening to Advance Drug Discovery and Development
News

South Africa’s CPGR Turns to Cell-Culture Based Screening to Advance Drug Discovery and Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "South Africa’s CPGR Turns to Cell-Culture Based Screening to Advance Drug Discovery and Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CPGR (CT, South Africa) has announced that it has entered into an agreement with SimuGen (KL, Malaysia), involving the development of novel biomarker assays for the prediction of toxicity of existing and novel drug compounds.

The CPGR was founded in 2006 as part of a government initiative to provide scientists in South Africa with analytical services, technical expertise, project support and collaborative research capabilities in the genomics and proteomics arena.

The organization has a particular interest in translational research and advancing scientific findings from the bench to the clinic, including a focus on tackling pressing health needs in Africa. Today, CPGR is becoming a global biotech player, venturing into fields such as molecular diagnostics and drug discovery.

“We realized very early in our activities the potential value in a number of fields of combining our information-rich analytical capabilities with innovative cell culture models” said Reinhard Hiller, Ph.D., Managing Director of the CPGR.

“The work we will do with Simugen, aimed at improving the ability to develop novel, safe drugs, fits perfectly into our vision of creating cutting-edge ex-vivo drug screening workflows that make full use of our genomic & proteomic platforms,” Hiller said.

Said Dr Quin Wills, CSO of SimuGen, “We believe that the greatest pharmacogenomics gains over the next few years are to be had within early stage drug discovery. This means the coming together of the best genomic modeling, genomic technologies and high throughput biological models. We are pleased to be working with a team that has the same vision for high quality science that can really help facilitate a compound go/no go decision.”
Advertisement